Monoclonal antibody | |
---|---|
Type | Whole antibody |
Source | Human |
Target | SIGLEC8 |
Clinical data | |
Trade names | AK002 |
Routes of administration | Intravenous |
Identifiers | |
CAS Number | |
UNII | |
KEGG | |
ChEMBL | |
Chemical and physical data | |
Formula | C6408H9884N1700O2006S46 |
Molar mass | 144310.21 g·mol−1 |
Lirentelimab (sold under the brand name AK002) is a humanized nonfucosylated monoclonal antibody that targets sialic acid-binding Ig-like lectin 8 ( SIGLEC8). In a randomized clinical trial, lirentelimab was found to improve eosinophil counts and symptoms in individuals with eosinophilic gastritis and duodenitis. [2] Adverse reactions include infusion reactions, which are mild to moderate and typically occur following the first infusion. [3]
In individuals with asthma, Siglec-8 expression is increased on the surface of eosinophils and mast cells in sputum. [4] Lirentelimab depletes eosinophils via antibody-dependent natural killer cell mediated cytotoxicity.
As of 2023, lirentelimab has no approved indications. [5]
Lirentelimab is a humanized, nonfucosylated IgG1 monoclonal antibody that targets Siglec-8. [6] Siglec-8 is an inhibitory receptor present on eosinophils and mast cells, with low level expression on basophils. [2] [7] Interleukin-5, granulocyte-macrophage colony stimulating factor, and interleukin-33 enhance anti-Siglec-8 mediated destruction of eosinophils. [7] Lirentelimab inhibits mast cells' IgE-mediated degranulation and de novo synthesis of prostaglandin D2 in vitro. [7]
Mild-to-moderate infusion reactions may occur with lirentelimab, which tend to occur following the first infusion only. [3]
Lirentelimab has been studied for the treatment of chronic spontaneous urticaria, indolent systemic mastocytosis, and severe allergic conjunctivitis. [6]